Public and patient involvement in developing a survey on re-consent for pediatric genomic data sharing in Japan: a GRIPP2-LF report Authors: Hiroko Terui-Kohbata, Midori Yamamoto, Tomoyo Takeuchi Published: 2026 ABSTRACT AbstractBackground. In Japan, adolescents who entered genomic research under proxy consent are asked to re-consent at age 16 for newly collected data, while previously collected data remain usable without consent. Public perspectives on re-consent and data sharing are not well understood. To prepare a survey for adolescents, we used public and patient involvement (PPI) to refine the questionnaire and information sheet. Methods. Four stages of PPI were conducted: a kickoff meeting, two rounds of web-based feedback, and a final discussion. Five PPI members (aged 20–60 s, diverse backgrounds) provided iterative feedback on survey design, wording, and framing. All revisions were documented using GRIPP2–Long Form. Results. PPI members expressed diverse views on re-consent and acceptable secondary data use, supporting the relevance of the survey design. Feedback resulted in major revisions, including clearer terminology, unified wording, improved explanations of parent–child context, existing versus newly collected data, age categorization, and Japan’s opt-out procedures. Of 36 comments in the first round, 30 (83%) were incorporated; of 23 comments in the second round, 20 (87%) were incorporated. Conclusion. PPI enhanced the clarity, cultural relevance, and acceptability of materials for a survey on re-consent in pediatric genomic data sharing. As one of the first systematic PPI reports from Japan, this work demonstrates how systematic involvement strengthens ethically sensitive research and provides a transparent foundation for forthcoming surveys.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12687-026-00907-6.Keywords: Public and patient involvement (PPI), Re-consent, Pediatric genomic research, Data sharing, Japan Introduction Genomic data sharing is widely recognized as essential for advancing science and medicine. However, the participation of minors raises ethical complexities. In Japan, national research ethics guidelines specify that adolescents aged 16 years and older are eligible to provide their own consent. Therefore, children typically join genomic research based on proxy consent from parents. At age 16, participants who joined genomic research under proxy consent are asked for re-consent for newly collected data, while prior data and samples remain usable without consent (Ministry of Education Culture, Sports, Science and Technology et al. 2021). In contrast, international practices increasingly require explicit re-consent from participants once they reach adulthood, before their previously collected data or biospecimens can continue to be used or shared. The Global Alliance for Genomics and Health’s (GA4GH’s) KIDS framework has been validated through a Delphi study in Canada, showing strong convergence among clinicians, genomic researchers, and ethicists that obtaining re-consent from participants upon reaching the age of consent, along with transparent data governance are essential in pediatric genomic research (Rahimzadeh et al. 2021). Re-consent is further reinforced as an ethical requirement when participant data or samples continue to be used over time, as discussed by Murdoch et al. (2023), and is consistent with GA4GH’s regulatory guidance under GDPR (GA4GH, 2022). Patrinos et al. further emphasize that broad consent alone may be insufficient in pediatric data-sharing contexts, highlighting the need for flexible consent clauses that enable future re-consent and maintain transparency and trust between researchers and participants (Patrinos et al. 2022). These international trends highlight differences from Japanese guidelines, thereby raising questions about autonomy and long-term data governance. Internationally, these frameworks and initiatives also emphasize progressive assent and eventual re-consent by minor participants to ensure respect for developing autonomy (Knoppers et al. 2014). In our previous work, we examined re-consent practices in Japanese biobanks and highlighted challenges related to age thresholds, communication strategies, and governance structures (Terui-Kohbata et al. 2025). That study demonstrated that both researchers and ethics committees in Japan face uncertainty in applying re-consent requirements. To address these challenges, it is essential to understand how adolescents themselves perceive re-consent and data sharing. However, designing a survey on such ethically complex topics requires materials that are comprehensible and culturally sensitive for young participants. Therefore, we incorporated public and patient involvement (PPI) in the development process to co-create clear and accessible research materials—including the questionnaire and participant information sheet—for a national survey targeting adolescents. While numerous European and North American studies have reported structured applications of PPI based on the Guidance for Reporting Involvement of Patients and the Public 2 (GRIPP2) framework (Staniszewska et al. 2017; Weschke et al. 2023), systematic reports from Japan remain scarce, particularly in the field of pediatric genomics. This study addresses this gap by documenting one of the first structured PPI practices conducted in Japan. Our PPI process was embedded throughout the design of a survey to explore public and adolescent perspectives on re-consent and data sharing. This report follows the GRIPP2-Long Form framework (Staniszewska et al. 2017), which has been widely adopted internationally (Staniszewska et al. 2011; Weschke et al. 2023) but rarely applied in Japan. Methods Design of the PPI process The PPI activity was conducted to obtain public and patient input on the questionnaire and participant information sheet for a national survey on adolescents’ views of re-consent and data sharing, rather than to collect research data about the PPI contributors themselves. This activity was part of a multi-year research project on pediatric genomic data sharing funded by JSPS KAKENHI [Grant Number 23K09573]. The survey was designed as a web-based, scenario-based questionnaire targeting adolescents. In the hypothetical scenario, respondents are asked to imagine that their genomic and health information had been collected in childhood under maternal proxy consent and to consider how they would feel about providing individual re-consent at age 16. The questionnaire (which includes the full scenario) and its accompanying participant information sheet were the main materials reviewed through the PPI process. The complete questionnaire and information sheet are provided in the Supplementary materials (see Supplementary File S1 for the final questionnaire and Supplementary File S2 for the final information sheet). The four-step design was chosen to ensure iterative refinement of the survey documents and to provide opportunities for both remote and face-to-face engagement, in line with GRIPP2-LF recommendations. The process consisted of: Kickoff meeting (October 2024): Introduction of research aims and initial exchange of views on re-consent. Kickoff meeting (October 2024): Introduction of research aims and initial exchange of views on re-consent. First round of web-based feedback (December 2024): Comments on draft materials, including the questionnaire and participant information sheet (see Supplementary File S3 for the initial information sheet and Supplementary File S4 for the initial questionnaire). First round of web-based feedback (December 2024): Comments on draft materials, including the questionnaire and participant information sheet (see Supplementary File S3 for the initial information sheet and Supplementary File S4 for the initial questionnaire). Second round of web-based feedback (February 2025): Comments on revised materials. Second round of web-based feedback (February 2025): Comments on revised materials. Final discussion session (March 2025): Synthesis of feedback and confirmation of revisions. Final discussion session (March 2025): Synthesis of feedback and confirmation of revisions. PPI members Five PPI members were invited to ensure diversity in age (20–60 years) and gender. They were selected from citizen representatives participating in the Japan Agency for Medical Research and Development (AMED) Genome Medicine Realization Platform: Biobank Utilization Program, Social Co-Creation Domain (Principal Investigator (PI): Masayuki Yoshida). They had collaborated with researchers in this program for approximately 2.5 years, and thus had developed a working knowledge of genomic research through prior collaboration in addition to their diverse occupational backgrounds (e.g., middle school teacher, company employee, Non-Governmental Organization (NGO) staff, patient group representative). Remuneration was set at 3,000 Japanese yen (JPY) per hour plus reimbursement of transportation expenses. Data collection and analysis The two rounds of web-based surveys were conducted using the Questant® platform. The information sheet corresponded to the explanatory section of the informed consent documents typically used in Japan. For each item in the information sheet and the questionnaire, PPI members were first asked whether revisions were necessary; if they answered ‘yes,’ they were invited to provide free-text comments. All collected comments were reviewed by three researchers, who assessed each suggestion for its relevance, clarity, and feasibility, and discussed whether and how it should be incorporated. When comments were adopted, a corresponding revision plan was formulated; when they could not be reflected, the rationale was documented. A comprehensive tracking table (comment matrix) was created, listing all comments together with either the corresponding revision plan or the rationale for non-adoption. This table was returned to the PPI members for their review and confirmation. Items for which consensus could not be reached through web surveys and discussions among researchers were addressed in a face-to-face discussion session with PPI members. The session was held in an easily accessible conference room to facilitate participation from members living outside the region. During this session, alternative revision strategies were proposed and discussed, and a final revision plan was confirmed collaboratively. The finalized materials were subsequently circulated to all PPI members for their review, and final agreement was obtained. This PPI activity did not constitute human subjects research under Japanese regulations; therefore, approval from an ethics review committee was not required. Results The initial survey materials contained technical terms and abstract phrasing that posed comprehension challenges for lay readers. Through the PPI process, iterative feedback progressively improved clarity and acceptability, as described below. The PPI process confirmed both the feasibility and value of citizen involvement in developing bioethical survey instruments. Kickoff meeting PPI members successfully understood both the purpose of the adolescent-targeted survey—namely, to explore the ethical issues surrounding individual re-consent in genomic research—and the purpose of the PPI activity itself, including their role in reviewing and improving the survey materials and the overall project schedule. They expressed a wide range of views regarding the necessity of re-consent and the acceptable scope of data use. This diversity of perspectives helped confirm that the response options included in the questionnaire—covering medical, academic, and industrial/commercial uses—were appropriate and sufficiently comprehensive. Some members noted that the relationship between the proxy decision-maker and the adolescent could influence how adolescents form their own views on re-consent. As a result, the hypothetical scenario used in the adolescent-targeted web-based survey—which asks respondents to imagine how they would feel about re-consenting in a situation where their genomic data had been collected in childhood—was revised to specify the proxy as the mother. In addition, a confirmation note was added to the information sheet to remind respondents that, if the mother–child framing in the scenario caused discomfort or distress, they could discontinue the survey. First and second round feedback To ensure shared understanding with the PPI members, supporting materials explaining both the methodology of the adolescent-targeted web-based scenario survey and the procedures for submitting feedback in the PPI process were provided to members prior to the first round. In the first round, 36 comments were received (8 on the information sheet and 28 on the questionnaire), of which 30 were incorporated (83%). Most comments focused on improving comprehensibility and clarity, such as unifying terminology (e.g., “child” vs. “children”), simplifying technical expressions, and clarifying the rationale for using a scenario-based method. Further refinements to the information sheet included clarifying honorarium procedures (to reassure participants that points would be granted even if they discontinued) and adding researchers’ affiliations to enhance transparency. In addition, the questionnaire was revised by adjusting the wording of emotional scale items based on the semantic differential (SD) method—for example, by replacing ‘miserable’ with ‘pitiful’ and by standardizing the left–right orientation of the positive and negative terms. In the second round, 23 comments were received (8 and 15, respectively). Eighteen were incorporated directly, while two could not be resolved within the research team and were deferred for discussion with PPI members in the subsequent face-to-face session. Ultimately, 20 of the 23 comments (87%) were incorporated. Feedback at this stage centered on refining ethical framing and procedural transparency, including revisions to overly formal wording (e.g., “to give consent” → “to consent”), clarification of the 16-year threshold for re-consent, adjustments to age categories, and the addition of an explanation of Japan’s opt-out procedures. One example of a comment for the questionnaire not adopted concerned the question in which adolescent respondents, after imagining themselves as participants whose data had been collected under maternal proxy consent, were asked whether their own individual consent was necessary. This item offered four response options—“absolutely necessary,” “somewhat necessary,” “not very necessary,” and “not necessary at all.” A PPI member suggested adding a neutral option such as ‘either is fine,’ but the research team decided against this, reasoning that such an option is often over-selected in Japanese surveys and could obscure whether respondents viewed individual re-consent as necessary. Representative examples are summarized in Table 1 (information sheet) and Table 2 (questionnaire), while the full list of comments and revisions is provided in Supplementary File S5 (First Round) and Supplementary File S6 (Second Round). The finalized information sheet is provided in Supplementary File S2. Table 1Feedback and revisions for the information sheet from PPI membersCategoryFeedback exampleRevision madeTerminologyInconsistent use of “child” vs. “children”Unified terminology across the documentWording / Phrasing“To give consent” sounded too technicalRevised to “to consent,” making it simpler and more participant-friendlyScenario method explanationPurpose of scenario method unclear; PPI members asked why this method was usedAdded a brief explanation stating that the scenario method helps participants think of “research participation” and “consent” as their own matterScenario framingProxy identity unclear; mother–child framing may cause discomfortSpecified the proxy as “mother” and added a note allowing respondents to discontinue if the scenario caused discomfortConsent threshold“Why 16 years, not 18?”Explained the relevant national ethical guideline to PPI members during the review process (not added to the questionnaire)Emotional considerationsInstruction “please refrain” was too weakRevised to stronger wording (“please stop if distressed”)VoluntarinessConcerns about honorarium if discontinuingClarified that honorarium/points would still be granted even if participation was discontinuedTransparencyParticipants may want to know researcher backgroundAdded researchers’ affiliations to improve transparency Feedback and revisions for the information sheet from PPI members Table 2Feedback and revisions for the questionnaire from PPI membersCategoryFeedback exampleRevision madeTerminologyTechnical terms (e.g., “biospecimen”) difficultReplaced with concrete term “blood”ComprehensibilitySome response options were abstract/ambiguousSimplified and clarified choicesScenario explanationPurpose of using a scenario-based questionnaire unclearAdded brief explanation of the rationale for the scenario methodAge categoriesMix of grade-based and age-based categories caused confusionAligned grade-based categories for younger children (per guidelines), added “pre-school age,” and grouped re-consent-eligible respondents as “16 years or older”Scale designEmotional terms and polarity unclear (e.g., “miserable”)Revised wording (e.g., “pitiful”), standardized positive/negative placement, and adjusted layout for readabilityOpt-out proceduresLack of explanation of Japan’s opt-out proceduresAdded explanatory text on the current opt-out procedure and adopted a two-question structure : (1) whether the current procedure is appropriate, and (2) preferred alternativesSecondary use of data“It feels uneasy not to know how far my data are used”Introduced a two-step format: (i) whether use beyond Study A is permitted, (ii) acceptable scope of secondary useExamples in items“Anthropology” example unclear; “medical research without genetic info” ambiguousRemoved “anthropology” example, deleted the ambiguous item, and revised phrasing to “fields other than medical research” Feedback and revisions for the questionnaire from PPI members Final discussion PPI members emphasized several points: that the categories of secondary use presented in the questionnaire—where the hypothetical study focuses on juvenile-onset diabetes—were helpful but should be accompanied by multiple concrete examples for each category. These categories included (1) other medical research related to diabetes (the target condition of the hypothetical study), (2) medical research unrelated to diabetes, (3) non-medical academic research, (4) product development in healthcare, and (5) product development unrelated to healthcare. PPI members noted that providing several examples for each category would help avoid suggesting a preferred direction and make the distinctions clearer for respondents. They also emphasized that distinctions between academic and industrial use, and between research and development, are difficult for laypersons yet important to articulate clearly. Accordingly, the questionnaire was revised to present each category with multiple illustrative examples—for instance, diabetes-related medical research, non-diabetes medical research (e.g., hypertension, cancer), non-medical academic research (e.g., origins of the Japanese population), product development in the healthcare field by for-profit companies (e.g., drugs, diagnostic kits), and product development outside the healthcare field by for-profit companies (e.g., cosmetics, health foods). In addition, PPI members suggested that this item would be easier to understand if it were asked in two steps—first whether secondary use should be allowed, and then, only if permitted, how far such use should extend. Based on this feedback, the questions were revised into a two-step format: first asking whether data could be used beyond the initial study, and, if permitted, then asking respondents to specify the acceptable scope of secondary use. The finalized questionnaire incorporating all revisions is provided in Supplementary File S1. Discussion This study demonstrates that PPI substantially improved the clarity, acceptability, and cultural appropriateness of a complex bioethical survey on re-consent for pediatric genomic data sharing in Japan. By directly engaging citizens with prior experience in genomic research collaboration, we identified linguistic ambiguities, conceptual misunderstandings, and relational dynamics that would have been difficult to detect solely through researcher-driven revision. As systematic documentation of PPI in Japan remains limited—particularly in pediatric genomics—this report contributes to filling a notable gap in the literature. Several concrete improvements illustrate the practical value of PPI (see Supplementary Files S5–S6). Comments in the first round led to revisions that unified terminology (e.g., “child” vs. “children”), replaced technical expressions with more accessible wording (e.g., “to give consent” → “to consent”), clarified scenario-based methods, and refined semantic differential scales by replacing emotionally loaded terms and standardizing polarity. One member raised the question, “Why is re-consent set at 16 years?”, which led the research team to explain the relevant provisions of Japan’s national research ethics guidelines during the PPI process. This clarification helped ensure that PPI members shared the regulatory understanding needed to provide informed feedback on the survey materials, although this background information was not added to the questionnaire itself. PPI also illuminated relational and socio-cultural issues specific to the Japanese context. Feedback from the kickoff meeting indicated that the identity of the proxy decision-maker could influence adolescents’ perceptions of re-consent. This led to specifying the mother as the proxy in the hypothetical scenario and adding a note to reassure respondents that they could discontinue the survey if the framing caused discomfort. These insights underscore how PPI can uncover assumptions embedded in research materials and encourage revisions that respect cultural norms around parental authority and family decision-making. In later stages, PPI members emphasized the need to provide examples for each category of secondary use to help respondents understand the distinctions. The research team further noted that relying on a single example could introduce undue framing effects. Based on this shared recognition, the questionnaire was revised to include multiple illustrative examples for each category of secondary use. This feedback was incorporated by adding several illustrative examples across five categories (e.g., medical research, non-medical academic research, healthcare product development). Members also highlighted confusion between academia and industry, and between research and development—distinctions that were subsequently clarified through restructuring of response options. Notably, the suggestion to include a neutral response option (“either is fine”) in the re-consent necessity item was not adopted, due to the risk of obscuring meaningful attitudes—illustrating the importance of transparently documenting both incorporated and non-incorporated feedback, consistent with GRIPP2 principles. The diversity of perspectives within our PPI group reflected broader societal debates about pediatric genomic governance in Japan. Some PPI members stressed the intrinsic sensitivity of genomic information and the ethical necessity of individual re-consent, while others prioritized societal benefit and viewed parental permission as adequate under certain conditions. These divergences highlight the importance of incorporating heterogeneous viewpoints into the development of tools intended to inform policy discussions. Our findings resonate with international frameworks, including the KIDS framework (Knoppers et al. 2014). In addition, they align with recent adolescent-specific ethical guidance—such as the 2025 Society for Adolescent Health and Medicine (SAHM) Guidelines—which emphasize respect for emerging autonomy, inclusion of adolescents in study design, and the importance of culturally and developmentally appropriate research materials (SAHM, 2025). Similar to concerns raised in GDPR-oriented analyses (Shabani and Borry 2018), Japanese PPI participants expressed unease about the scope of secondary use—reinforcing that these are shared global issues. The challenges surfaced in this process, including addressing questions about Japan’s opt-out procedures and broader concerns about whether the national guideline— which does not require re-consent for continued use when no new data are collected—remains appropriate in light of international trends toward requiring explicit re-consent, are consistent with previous studies of re-consent practices in Japanese biobanks (Terui-Kohbata et al. 2025). Quantitatively, 83% of comments from the first round and 87% from the second round were incorporated, demonstrating a high level of influence on survey design. Qualitatively, PPI highlighted the need to address not only linguistic clarity but also procedural fairness, transparency of researcher affiliation, and participant reassurance regarding compensation. These lessons will inform both the next phase of survey development and the implementation of the forthcoming nationwide study. Specifically, they highlight the need to adopt more diversified recruitment strategies for the main survey and to develop structured metrics for evaluating the comprehensibility and cultural appropriateness of the questionnaire. This study has several limitations. PPI participants were adults previously engaged in genomic research for approximately 2.5 years, potentially limiting generalizability to populations without such familiarity. In particular, adolescents, who were the intended recipients of the questionnaire, were not involved as PPI contributors. Although adult PPI members provided valuable feedback on clarity, cultural acceptability, and ethical framing, their insights may not fully reflect adolescents’ own interpretations and priorities. Future initiatives should involve participants with diverse levels of familiarity, including adolescents themselves and those without prior exposure, with appropriate ethical and practical safeguards, to ensure broader representativeness (Brett et al. 2014; Greenhalgh et al. 2019). Although comments were carefully translated, some nuances may have been lost. Conclusion PPI significantly enhanced the design of a national survey on re-consent for pediatric genomic data sharing in Japan. As one of the first systematic PPI reports in this field from Japan, this study demonstrates both feasibility and value in incorporating public perspectives into the development of ethically sensitive genomic research materials. The finalized survey will be used in the next phase—a nationwide survey of adolescents, researchers, and the public—linking PPI directly to empirical data that can inform future policy-making. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Acknowledgements We gratefully acknowledge the collaboration of the five PPI members of the AMED Genome Medicine Realization Biobank Utilization Program (A study of promotion of biological specimen and data utilization and PPI strategy to establish genome medicine and research-leveraged society; PI: Masayuki Yoshida), who contributed their time and expertise to this project. Their valuable feedback on the information sheets and questionnaires throughout the study process substantially improved the clarity and relevance of the study materials. Author contributions HK conceived and designed the study, supervised the project, and secured funding. MY and TT contributed to data collection, coordination of the PPI activities, and critical revision of the manuscript. HK drafted the initial version of the manuscript. All authors contributed to the interpretation of data, revised the manuscript critically for important intellectual content, and approved the final version. Funding This work was supported by JSPS KAKENHI [Grant Number 23K09573]. Data availability Data supporting the findings of this study are available upon request from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Note: Tokyo Medical and Dental University was reorganized and renamed as Institute of Science Tokyo in 2024. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Change history 6/10/2026 The original online version of this article was revised: Supplementary Material 1 appears to be correct, but Supplementary Materials 2–6 do not correspond to the correct files. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Data Availability Statement Data supporting the findings of this study are available upon request from the corresponding author upon reasonable request.